Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial

All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT02546921) with the primary objective of exploring the safety a...

Descripción completa

Detalles Bibliográficos
Autores principales: Spicer, James, Basu, Bristi, Montes, Ana, Banerji, Udai, Kristeleit, Rebecca, Miller, Rowan, Veal, Gareth J., Corrigan, Christopher J., Till, Stephen J., Figini, Mariangela, Canevari, Silvana, Barton, Claire, Jones, Paul, Mellor, Sarah, Carroll, Simon, Selkirk, Chris, Nintos, George, Kwatra, Vineet, Funingana, Ionut-Gabriel, Doherty, Gary, Gould, Hannah J., Pellizzari, Giulia, Nakamura, Mano, Ilieva, Kristina M., Khiabany, Atousa, Stavraka, Chara, Chauhan, Jitesh, Gillett, Cheryl, Pinder, Sarah, Bax, Heather J., Josephs, Debra H., Karagiannis, Sophia N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368744/
https://www.ncbi.nlm.nih.gov/pubmed/37491373
http://dx.doi.org/10.1038/s41467-023-39679-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10368744/
https://www.ncbi.nlm.nih.gov/pubmed/37491373
http://dx.doi.org/10.1038/s41467-023-39679-9

Ejemplares similares